Sponsored by

Evidence that Endures: Optimizing Outcomes in ATTR-CM

This symposium will explore the evolving landscape of ATTR-CM, highlighting how increased disease awareness has contributed to earlier recognition and improved diagnosis rate. Faculty will review the importance of disease-modifying therapy and examine the clinical and real-world evidence supporting current treatment approaches, including the efficacy and safety profile of tafamidis. The discussion will also address practical strategies for monitoring disease progression, optimizing supportive and non-amyloid-specific therapies and implementing a holistic approach to patient management to help improve outcomes for individuals living with ATTR-CM.

With Otávio Rizzi Coelho-Filho (Brazil), Sumeet Mitter (USA), Stefano Perlini (Italy)